Anlotinib as a third-line or further treatment for recurrent or metastatic nasopharyngeal carcinoma: a single-arm, phase 2 clinical trial

Anlotinib as a third-line or further treatment for recurrent or metastatic nasopharyngeal carcinoma: a single-arm, phase 2 clinical trial

Abstract Background Treatment options beyond the first-line setting for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) are limited. The role of the multitarget tyrosine kinase inhibitor anlotinib in RM-NPC is unclear. Methods In this prospective, single-arm, phase 2 trial, patients with h...

Full description

Bibliographic Details
Main Authors: Yu Fang, Ning Su, Qihua Zou, Yi Cao, Yi Xia, Linquan Tang, Xiaopeng Tian, Panpan Liu, Qingqing Cai
Format: Article
Language:English
Published: BMC 2023-11-01
Series:BMC Medicine
Subjects:
Anlotinib
Nasopharyngeal carcinoma
Recurrent
Metastatic
Antiangiogenic therapy
Online Access:https://doi.org/10.1186/s12916-023-03140-x

Internet

https://doi.org/10.1186/s12916-023-03140-x

Similar Items